Tags

Type your tag names separated by a space and hit enter

Evaluation of the clinical efficacy of meloxicam in cats with painful locomotor disorders.
J Small Anim Pract 2001; 42(12):587-93JS

Abstract

The ability of two non-steroidal anti-inflammatory drugs to modify the clinical manifestations of pain associated with locomotor disease was assessed. Sixty-nine cats with acute or chronic locomotor disorders were recruited from 14 first opinion UK veterinary practices and randomly allocated to one of two treatment groups. Group A received meloxicam drops (0.3 mg/kg orally on day 1 followed by 0.1 mg/kg daily for four more consecutive days) and group B received ketoprofen tablets (1.0 mg/kg orally once daily for five days). Each cat underwent a full clinical examination before treatment, 24 hours after initiation of treatment and 24 hours after completion of treatment. General clinical parameters (demeanour and feed intake) and specific locomotor parameters (weightbearing, lameness, local inflammation and pain on palpation) were scored using a discontinuous scale scoring system. The two groups did not differ in terms of age, weight, gender distribution or duration of clinical signs; nor did they differ in terms of general clinical or specific locomotor scores pretreatment. Both treatment regimens resulted in a significant improvement in demeanour, feed intake and weightbearing, and a significant reduction in lameness, pain on palpation and inflammation. No significant difference was observed between the two treatment groups with respect to any of the parameters measured and both treatments were associated with minimal observed side effects. Meloxicam and ketoprofen were found to be effective analgesics and well tolerated in cats with acute or chronic locomotor disorders when administered for short-term treatment (five days) in such cases. However, meloxicam was assessed to be significantly more palatable than ketoprofen.

Authors+Show Affiliations

College of Veterinary Medicine, University of Florida, Gainesville 32610, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

11791773

Citation

Lascelles, B D., et al. "Evaluation of the Clinical Efficacy of Meloxicam in Cats With Painful Locomotor Disorders." The Journal of Small Animal Practice, vol. 42, no. 12, 2001, pp. 587-93.
Lascelles BD, Henderson AJ, Hackett IJ. Evaluation of the clinical efficacy of meloxicam in cats with painful locomotor disorders. J Small Anim Pract. 2001;42(12):587-93.
Lascelles, B. D., Henderson, A. J., & Hackett, I. J. (2001). Evaluation of the clinical efficacy of meloxicam in cats with painful locomotor disorders. The Journal of Small Animal Practice, 42(12), pp. 587-93.
Lascelles BD, Henderson AJ, Hackett IJ. Evaluation of the Clinical Efficacy of Meloxicam in Cats With Painful Locomotor Disorders. J Small Anim Pract. 2001;42(12):587-93. PubMed PMID: 11791773.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of the clinical efficacy of meloxicam in cats with painful locomotor disorders. AU - Lascelles,B D, AU - Henderson,A J, AU - Hackett,I J, PY - 2002/1/17/pubmed PY - 2002/5/29/medline PY - 2002/1/17/entrez SP - 587 EP - 93 JF - The Journal of small animal practice JO - J Small Anim Pract VL - 42 IS - 12 N2 - The ability of two non-steroidal anti-inflammatory drugs to modify the clinical manifestations of pain associated with locomotor disease was assessed. Sixty-nine cats with acute or chronic locomotor disorders were recruited from 14 first opinion UK veterinary practices and randomly allocated to one of two treatment groups. Group A received meloxicam drops (0.3 mg/kg orally on day 1 followed by 0.1 mg/kg daily for four more consecutive days) and group B received ketoprofen tablets (1.0 mg/kg orally once daily for five days). Each cat underwent a full clinical examination before treatment, 24 hours after initiation of treatment and 24 hours after completion of treatment. General clinical parameters (demeanour and feed intake) and specific locomotor parameters (weightbearing, lameness, local inflammation and pain on palpation) were scored using a discontinuous scale scoring system. The two groups did not differ in terms of age, weight, gender distribution or duration of clinical signs; nor did they differ in terms of general clinical or specific locomotor scores pretreatment. Both treatment regimens resulted in a significant improvement in demeanour, feed intake and weightbearing, and a significant reduction in lameness, pain on palpation and inflammation. No significant difference was observed between the two treatment groups with respect to any of the parameters measured and both treatments were associated with minimal observed side effects. Meloxicam and ketoprofen were found to be effective analgesics and well tolerated in cats with acute or chronic locomotor disorders when administered for short-term treatment (five days) in such cases. However, meloxicam was assessed to be significantly more palatable than ketoprofen. SN - 0022-4510 UR - https://www.unboundmedicine.com/medline/citation/11791773/Evaluation_of_the_clinical_efficacy_of_meloxicam_in_cats_with_painful_locomotor_disorders_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0022-4510&date=2001&volume=42&issue=12&spage=587 DB - PRIME DP - Unbound Medicine ER -